The Treatment of Symptoms Following Spike Protein Exposure

Cyma Technologies Article Spike Protein study

The Treatment of Symptoms Following Spike Protein Exposure

The Treatment of Symptoms Following Spike Protein Exposure

With Therapeutic Sound

A Personal Observational Study With The AMI 500

Abstract: This study examines the phenomenon called “shedding” and the effects of using a frequency emitting device to address some common symptoms experienced by those who show sensitivity to people who have been vaccinated.  After the Covid19 vaccine became available, stories began emerging of unvaccinated individuals becoming ill after being in close proximity to those recently vaccinated. This was confusing to many, as it had been stated unequivocally that the mRNA technology, in theory, should not be able to “shed.”

By far, the most common symptom of shedding is unusual and disruptive menstrual bleeding, which is also the most common Covid vaccine injury.  After this, the symptoms most experienced were headaches, flu-like symptoms, nosebleeds, fatigue, rashes, tinnitus, sinus or nasal issues and shingles. Other symptoms also repeatedly seen are heart palpitations, herpes outbreaks and hair loss. Additionally, those effected report the experience of smelling a unique foul odor when they are near those recently vaccinated.

For the purpose of this study, we will be focusing on the symptoms of debilitating headaches, inability to be in large groups of people and experiencing a specific foul odor, when being in close proximity to a vaccinated person, as experienced by the subject in this preliminary study.

Key words: Covid vaccination, shedding, headaches, emotional stress, inability to interact socially or perform daily duties with covid vaccinated individuals.

Participant :

A 54 year-old woman in good health, on no medications, and non-vaccinated was suffering from headaches which came on suddenly after exposure to other individuals who had been vaccinated. She reported the experience of being overwhelmed by a certain foul odor when she encountered covid vaccinated individuals, or even items such as cardboard boxes or clothing that had come in contact with them.

She contacted Cyma Technologies to inquire as to whether there was a specific protocol for those suffering from symptoms related to covid vaccine shedding.  Despite trying numerous techniques, she had been unsuccessful in addressing the painful headaches and foul odor she experienced, which often resulted in her being bedridden for days.

Her husband was forced to take over the duties she usually performed, (such as going to the grocery store), in order to help her limit her exposure to the toxins. She became home-bound for the most part, and their social life diminished greatly. For safety purposes, her husband was forced to leave his clothing in the garage after handling estate sales, and do extensive body cleansing before entering their living space. The sensitivity she experienced created difficulties in her personal relationships and caused her to avoid contact with neighbors and friends.

Becoming increasingly hyper-sensitive, she delved into research on what could be causing this, as there were seemingly no medical professionals to consult on these issues. The unusual problem of smelling a foul odor which other individuals could not, raised suggestions by her health practitioners that perhaps there were mental and emotional issues involved.

She had experimented with several sound protocols for headaches and pain relief, along with consulting a toxin specialist from the Tennant Institute, who created a remedy to attempt to offset the spike protein. While it reduced the duration of the headaches, it did not eliminate nor prevent them—nor did it do anything for the pain. She also tried BioGeometry biosignatures, acetaminophen, ibuprofen, turmeric and magnesium to relieve the pain which she reported as a 10 on a scale from 1-10.  She had tried many supplements and took the following ones on an ongoing basis to support her health: Basic multi-vitamins to include B, C and D, along with magnesium, milk thistle, acetyl-cysteine, a combo supplement for brain support and zinc/fulvic acid.

Her understanding of the limited research she was able to discover on the internet, was that the vaccine spike protein caused the zeta potential between red blood cells to collapse, leading to a clumping of the red blood cells. She suspected that this could be a potential cause of devastating headaches and pain in her head. She had also concluded from her studies that these symptoms were fairly widespread amongst both vaccinated and unvaccinated individuals when exposed to spike proteins. She did try a remedy she found online for the zeta potential issue, which also netted no results.

The Method :

Cyma Technologies manufactures an AMI 500 hand-held device which allows users to place it on designated areas of the body for specific health goals. After interviewing this participant, a protocol was devised for the use of the Oxygenation Optimization thirty-minute channel in these variations:

The first was to use the device every day as instructed for a thirty-minute pre-programmed session that included the specific “Three Point System” technique. This involved placing the device on her solar plexus and the palms of both hands, which is the suggested use of the device during Channel One for Oxygen Optimization for thirty-minutes once a day. For this subject and the purposes of the study, Cyma Technologies devised several variations for use of the AMI 500.

The second variation included using the device in advance of meeting other people when she could predict these occasions. This could include having the device on her person running the channel during her encounters, which meant she would possibly have to use the device more than once in a day. She devised a “pouch” to place the AMI 500 in, to wear around her neck, similar to a shoulder bag.

The third variation was to be utilized only if she had unexpected encounters. She was to use the channel immediately following—even if she had already done a channel that day. In addition, she was to wear it on her body when entering public places and when possible, have the channel running as a protective measure.

Subject’s Statement :

“The first thing I noticed is that when I would play the channel immediately after an encounter or exposure to the spike protein, the channel eliminated the headache right away. At first, it was hard to believe. This gave me such a sense of hope and quelled the anxiety that I had developed in anticipation of each time I was to encounter someone who had been vaccinated. I was fearful that I would be required to be in a public place.

In the first 12 weeks of using the protocol, I was exposed to spike proteins 35 times and only suffered 11 headaches. Since that time, my symptoms have improved dramatically, with very few headaches and those were diminished or alleviated almost immediately, by the use of the AMI 500 device.

I also found that after this initial stage of two six-week protocols, I could begin to interact with people for short amounts of time (10-20 minutes) and not get the headache. It seemed that the more days I was on the protocol, the better it was working. It took some acclimation time, but I had a sense that it was beginning to change my responses fairly early on.

I also found that if I was in too large of a crowd or made too many stops in my outings, that it would lead to a headache, but the device was still able to eliminate the headache when I returned home. Sometimes, I simply forgot to take it with me, especially after my symptoms started improving.

After four six-week protocols of daily use of the device, it was recommended that I try a “maintenance protocol” of only three times per week, instead of daily. I discovered right away, that at this point of use, I still needed to use the daily protocol of one thirty-minute Oxygen Optimization channel. Without this, if I had an encounter, I would get an immediate headache that would not go away. My fear of going into public places also returned after two experiences that showed me I still needed the protective energy of the device. I returned to the original daily protocols and am still experiencing the success of using it.

I can now, as of the end of March 2026, run into a public restroom for a short break during road trips for business without the device. I can now go to the grocery store and perform other errands, as long as I have the device on me and running. I usually have it in my cloth back pack on my body. I can eat in a public restaurant, as long as I keep the device running. I usually keep it next to my body, out of sight. If we are there for longer than thirty-minutes, I re-start the channel.

I can’t begin to tell you how much this has helped my life. To have the AMI 500 has returned my ability to live my life and interact with those I love. I will continue to use my daily thirty-minute protocol; and at some point, try to operate with a maintenance protocol.

I have committed to a second phase of this preliminary research so that we can see if it is possible to reach another level of improvement with the AMI 500 device.”

Dr. Cromwell’s statement:    

“From our live blood cell microscopy studies, we have determined that Channel One Oxygen Optimization can reduce red blood cell clumping, increase white blood cell motility, (which boosts the immune system response), as well as decreases uric acid and the amount of bacteria and viruses in the blood.

It is not surprising that this single channel applied to her solar plexus with the AMI 500 was successful in fortifying multiple body systems. All AMI devices operate utilizing the meridian system which we access with sound, allowing the healing energy to cross into the physical from the subtle bodies.  The ability of the frequencies to influence the cell membrane assists in building the cell integrity, which we would postulate was partnering with the immune system to build her defenses against the damages caused by the spike protein.

In the study conducted by Rutgers University Professor Sungchul Ji and acoustics researcher John Stuart Reid, the frequencies from Cyma Technologies AMI devices increased blood oxygen 15%, and cell viability, (which is the measurement of the proportion of healthy living cells within a sample population), with an increase of 365%. Given these statistics, it is not unusual to expect that her fortified blood would be able to combat the break-down of cell function and prevent the devastating headaches. By wearing the device on her person, it was able to strengthen her natural protective toroidal field, to create energetic boundaries between her and the person shedding.

From the improvements we have seen to date, it is my professional opinion that if the subject continues to use this protocol she will eventually be able to reestablish patterns of health in these areas:

  • emotional health by reconnecting with those in her community, as well as eliminating the anxiety response of anticipating headaches due to toxicity exposure.
  • physical vitality, due to the return of healthy blood cells interactions and oxygen optimization, as well as enhancement of the cellular functions that will inevitably help her to regenerate her health and natural vitality
  • Cymatherapy with the AMI 500 device will help to rebuild the energetic field around her, which is the basis for our continued health and vibrancy.

Given the modern-day world, with many environmental toxins, it is not far-fetched to think that we may all need devices to help protect us from future challenges that the body is unable to adapt to. With this study, the AMI 500 has proven to be a viable tool to help individuals with seemingly no solutions, to regain important parts of their lives, along with creating drug-free options for pain relief.”

Contributors:

Substack article “The Forgotten Side of Medicine” by the Midwestern Doctor
Live Blood Cell Microscopy Technician S. Whitley
John Stuart Reid acoustics researcher with Professor Sungchul Ji
Mandara Cromwell, DCM

Click here to be connected to a Cymatherapist for any questions regarding this preliminary study or the AMI 500 device.



Cyma Technologies